Pacira BioSciences, Inc. reported its financial results for the first quarter of 2026, revealing total revenues of $177.4 million, a 5% increase from $168.9 million in the same period last year. The growth was primarily driven by a 5% rise in net product sales, which reached $177.4 million, up from $167.6 million in Q1 2025. Notably, EXPAREL sales increased by 5% to $143.3 million, while ZILRETTA saw a 15% rise to $26.8 million. However, sales of bupivacaine liposome injectable suspension for veterinary use dropped significantly by 55%, attributed to timing issues with orders from commercial partners.
Operating expenses for the quarter totaled $170.5 million, up from $166.9 million in the prior year, leading to an operating income of $6.9 million compared to $2.0 million in Q1 2025. The increase in operating expenses was largely due to higher selling, general, and administrative costs, which rose by 8% to $93.9 million. The company reported a net income of $2.9 million, or $0.07 per share, down from $4.8 million, or $0.10 per share, in the previous year, reflecting a decrease in interest income and an increase in income tax expense.
In terms of strategic developments, Pacira has been active in expanding its product offerings and market reach. The company recently concluded patient enrollment in a Phase 3 study for ZILRETTA targeting osteoarthritis pain in the shoulder, with topline results expected later this year. Additionally, Pacira has entered into a partnership with LG Chem to commercialize EXPAREL in select Asia-Pacific markets, which includes an upfront payment of $2 million and future royalties on sales.
Operationally, Pacira's cash and cash equivalents stood at $144.3 million as of March 31, 2026, down from $158.5 million at the end of 2025. The company reported a decrease in accounts receivable and inventories, indicating a tightening of working capital. The total employee headcount increased slightly, reflecting ongoing investments in commercial capabilities. Looking ahead, Pacira anticipates continued growth driven by its product portfolio and strategic partnerships, while also navigating challenges related to global economic conditions and potential tariffs impacting its supply chain.
About Pacira BioSciences, Inc.
Pacira BioSciences specializes in developing and commercializing non-opioid pain management therapies, including long-acting local anesthetics, corticosteroids, and nerve block devices. Its core products—EXPAREL, ZILRETTA, and iovera—serve surgical, orthopedic, and pain relief markets, emphasizing opioid reduction and enhanced recovery. The company leverages proprietary drug delivery and nerve modulation technologies to provide safe, effective, and targeted pain solutions for diverse patient populations.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.